Frameshift Mutations of Human Gastrin Receptor Gene (hGARE) in Gastrointestinal Cancers with Microsatellite Instability

Department of Internal Medicine, University of Milan, Milano, Lombardy, Italy
Laboratory Investigation (Impact Factor: 3.68). 04/2002; 82(3):265-71. DOI: 10.1038/labinvest.3780420
Source: PubMed


Gastrointestinal tumors with DNA mismatch repair (MMR) defects show microsatellite instability (MSI) and harbor frameshift mutations in coding mononucleotide repeats of cancer-related genes (targets). We assessed MSI status in 233 sporadic gastrointestinal tumors. We classified as MSI-H (high-frequency microsatellite instability) 15 (10%) of 150 colorectal cancers and 13 (16%) of 83 gastric cancers. We searched for frameshift mutations in a coding poly(T)(8) tract within the gastrin receptor gene (hGARE), which has a potential role in gastrointestinal carcinogenesis. To this purpose, we screened 43 unstable tumors (including 15 hereditary nonpolyposis colorectal cancer cases previously classified as MSI-H), 98 stable tumors, as well as 3 MMR-deficient and 4 MMR-proficient gastrointestinal cancer cell lines. We found mutations in 8 (19%) of the 43 MSI-H tumors but in none of the 98 stable cancers. hGARE mutation frequency was similar in gastric (23%) and colorectal cancers, including sporadic (13%) and hereditary (20%) cases. All mutated tumors proved to harbor frameshift mutations in other cancer-related genes that are considered as targets in MSI tumorigenesis. The MMR-deficient and gastrin-sensitive LoVo colorectal cancer cells also showed a hGARE heterozygous frameshift mutation, but expressed only the mutated allele. All detected mutations can be predicted to generate a truncated protein carrying amino acid changes. On the basis of genetic findings, we propose hGARE as a new candidate target gene in MSI tumorigenesis. Functional studies are warranted to elucidate the mechanism by which the hGARE mutation might contribute to gastrointestinal carcinogenesis.

Download full-text


Available from: Antonio Mori, Apr 09, 2014
  • Source
    • "With regard to molecular basis of GC, at least two distinct pathways have been identified: one characterized by the successive accumulation of mutations in oncogenes and tumor suppressor genes, in which p53 plays a relevant role, the other, the MSI pathway, characterized by the accumulation of somatic alteration in the length of simple nucleotide repeats that identify a subset of GC with specific biomolecular features (Fiocca et al., 2001). Reported data (Renault et al., 1996; Halling et al., 1999; Iacopetta et al., 1999; Artunedo et al., 2000; Guo et al., 2000; de Manzoni et al., 2001; Palli et al., 2001; Sud et al., 2001; Czopek et al., 2002; Huiping et al., 2002; Inamori et al., 2002; Laghi et al., 2002; Lee et al., 2002; Takahashi et al., 2002; Yamada et al., 2002) vary considerably with regard to MSI, ranging from 9.5% to 37.8% in GCs. These variations may be partly explained by the differences between susceptible populations and by different etiological factors, and seem to be clearly linked to the number of cases investigated and to the type and number of markers used in the study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to clarify whether specific p53 mutations may have biological relevance in terms of disease relapse or death in gastric carcinomas (GC). Resected specimens from a consecutive series of 62 patients with GC undergoing potentially curative surgery were prospectively studied. The mutational status of exons 5-8 of the p53 gene was investigated in 62 cases using the PCR-SSCP and sequencing. Presence of microsatellite instability (MSI) was evaluated in 56 cases by analyzing loci highly sensitive of MSI. Twenty mutations of p53 were detected in 17 of the 62 cases analyzed (27%). Ten mutations (50%) occurred in highly conserved domains. According to the p53 specific functional domains: 4/20 mutations (20%) were in the L3 loop and 3/20 (15%) in LSH motif. Eight of the 56 GC resulted MSI-H, 5 (9%) MSI-L, and 43 (77%) MSI stable (MSS). None of the 8 (14%) MSI-H GC showed p53 mutations. p53 mutations were associated with intestinal histotype. Moreover, specific mutations in functional domain (L3 and LSH), together with advanced TNM stage, node involvement, depth of invasion, diffuse histotype, proved to be significantly related to quicker relapse and to shorter overall survival. Specific mutations in p53 functional domains, rather than any mutations in this gene, may be biologically more significant in terms of patients outcome, indicating that these mutations might have biological relevance to identify subgroups of patients at higher risk of relapse or death who might benefit from a more aggressive therapeutic approach.
    Full-text · Article · Sep 2004 · Journal of Cellular Physiology
  • Source
    • "Advances in molecular biology have revealed a consistent set of genetic alterations that may correspond to multi-step stomach cancer development. Aberrant expression and amplification of oncogenes such as c-met, c-myc, K-ras, c- erbB-21213141516, etc., inactivation of tumor suppressor genes such as p53, p16, Rb, DCC, APC, PTEN1718192021222324, etc, DNA ploidy and microsatellite instability25262728, abnormal transcript of genes related to metastasis like nm23, CD44, E-cadherin[29,30], etc., are reported common events in the steps of carcinogenesis. Newly found cancer related genes such as COX-2, survivin, metallothionein II and RUNX3, etc. were also expressed abnormally in gastric cancer3132333435363738. "

    Preview · Article · Jan 2003 · World Journal of Gastroenterology
  • Source
    • "Frameshift mutations occurred in 23% of the gastric cancers studied, 13% of sporadic and 20% of hereditary colorectal carriers, and all tumours also had frameshift mutations in other genes (Laghi et al. 2002). The gastrin-sensitive LoVo colorectal cancer cell line also showed a similar frameshift mutation in the CCK B receptor gene (Laghi et al. 2002). The results in this study led the authors to propose that the human CCK B receptor gene is a new candidate target gene possibly playing a role in the tumourigenesis of a fraction of MSI tumours. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper the possible roles of cholecystokinin (CCK), gastrin, or gastrin-related peptides and their receptors in human gastrointestinal diseases are reviewed. For CCK/CCK(A) receptors (CCK(A)-R), the evidence for their proposed involvement in diseases caused by impaired CCK release or CCK(A)-R mutations, pancreatic disorders (acute/chronic pancreatitis), gastrointestinal motility disorders (gallbladder disease, irritable bowel syndrome), pancreatic tumor growth and satiety disorders, is briefly reviewed. The evidence that has established the involvement of gastrin/CCK(B)-R in mediating the action of hypergastrinaemic disorders, mediating hypergastrinaemic effects on the gastric mucosa (ECL hyperplasia, carcinoids, parietal cell mass), and acid-peptic diseases, is reviewed. The evidence for their possible involvement in mediating growth of gastric and pancreatic tumours and possible involvement of gastrin-related peptides in colon cancers, is reviewed briefly.
    Preview · Article · Jan 2003 · Pharmacology & Toxicology
Show more